- Home
- LABT
as of 10-30-2026 3:40pm EST
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | UNIVERSITY PARK |
| Market Cap: | 670.6K | IPO Year: | 2026 |
| Target Price: | $7.50 | AVG Volume (30 days): | 607.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $6.85 | Next Earning Date: | 11-18-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.05 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Compare LABT vs Leading Stocks
See how LABT stacks up against similar companies in the market
Head-to-Head Comparisons
More Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.